Gene therapy candidate TSHA-102 for Rett syndrome receives key designation, paving the way for an accelerated regulatory pathway.
The recently-listed Hong Kong construction firm's shares plummeted to all-time lows, triggering multiple volatility halts amid a lack of news.
The battery manufacturer secured a key grant to modernize its production facilities and expand workforce development programs.
The company outlined key milestones for its sublingual drug delivery platform, including a planned 2025 FDA submission for its high-dose aspirin.
Zepzelca combo becomes first approved maintenance treatment for extensive-stage small cell lung cancer, a historically difficult-to-treat disease.
The strategic move strengthens the AI firm's balance sheet as it accelerates its Web 3.0 data monetization and supercomputing initiatives.
The move pressures credit bureaus, with competitors TransUnion and Equifax seeing their stock prices fall sharply in response.
Shares surge over 26% after the company announces its largest US order in three years for 50,000 mining machines.